| Literature DB >> 12221472 |
K Assmann1, D Nashan, S Grabbe, T A Luger, D Metze.
Abstract
Interleukin-2 (Il-2) is widely used for treatment of carcinomas, leukemia, and melanoma. Adverse drug effects of Il-2 include various systemic and generalized cutaneous drug reactions. In the following we report on a persistent inflammatory reaction at the injection site of Il-2. A patient received chemoimmuno-therapy for treatment of metastasizing melanoma, including subcutaneous application of recombinant interleukin-2 (Proleukin((R))). Within a few days reddish nodules developed at the injection sites that persisted after cessation of Il-2 injections for two years until final lethal outcome. Histologic examination revealed a lobular panniculitis expressing atypical lymphocytes and multinucleated histiocytes.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12221472 DOI: 10.1007/s00105-001-0305-9
Source DB: PubMed Journal: Hautarzt ISSN: 0017-8470 Impact factor: 0.751